GLP-1 drugs have been transformative for treating obesity, but about 50 percent of patients who were prescribed this treatment ended up stopping due to severe side effects, such as nausea.
At the 2025 Society for Neuroscience meeting, experts presented new findings on how GLP-1 agonists’ action in the brain produced unwanted side effects and how these discoveries can guide future research.
Read more.
At the 2025 Society for Neuroscience meeting, scientists discussed the adverse side effects of GLP-1 agonists and new directions for future research.









